Everest Medicines (HKG:1952) acquired a license to MT1013 from Shaanxi Micot Pharmaceutical Technology to commercialize the drug, according to a Hong Kong bourse filing Thursday.
The firm will pay 200 million yuan upfront for the drug, and up to 1.04 billion yuan in milestone-related payments.
The license covers China and Asia-Pacific, excluding Japan. The drug is currently being studied as a treatment for secondary hyperparathyroidism, a kidney condition, in a phase 3 clinical trial in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments